GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (FRA:04K) » Definitions » Price-to-Owner-Earnings

Knight Therapeutics (FRA:04K) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-09), Knight Therapeutics's share price is €3.88. Knight Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Knight Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Knight Therapeutics was 731.82. The lowest was 8.32. And the median was 30.40.


FRA:04K's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.31
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Knight Therapeutics's share price is €3.88. Knight Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.11. Therefore, Knight Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-09), Knight Therapeutics's share price is €3.88. Knight Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €0.07. Therefore, Knight Therapeutics's PE Ratio without NRI for today is 54.65.

During the past 11 years, Knight Therapeutics's highest PE Ratio without NRI was 4025.00. The lowest was 10.52. And the median was 72.43.


Knight Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Knight Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Price-to-Owner-Earnings Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 515.00 17.37 - - -

Knight Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Knight Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Price-to-Owner-Earnings falls into.



Knight Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Knight Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.88/-0.21
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (FRA:04K) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Knight Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (FRA:04K) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Knight Therapeutics (FRA:04K) Headlines

No Headlines